BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, Kemp BJ, Grams MP, Morris JM, Hoover JM, Hu LS, Sarkaria JN, Brinkmann DH. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol 2013;15:1058-67. [PMID: 23460322 DOI: 10.1093/neuonc/not002] [Cited by in Crossref: 106] [Cited by in F6Publishing: 99] [Article Influence: 11.8] [Reference Citation Analysis]
Number Citing Articles
1 Bell C, Pannek K, Fay M, Thomas P, Bourgeat P, Salvado O, Gal Y, Coulthard A, Crozier S, Rose S. Distance informed Track-Weighted Imaging (diTWI): A framework for sensitising streamline information to neuropathology. NeuroImage 2014;86:60-6. [DOI: 10.1016/j.neuroimage.2013.07.077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Youland RS, Kitange GJ, Peterson TE, Pafundi DH, Ramiscal JA, Pokorny JL, Giannini C, Laack NN, Parney IF, Lowe VJ, Brinkmann DH, Sarkaria JN. The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neurooncol 2013;111:11-8. [PMID: 23086431 DOI: 10.1007/s11060-012-0986-1] [Cited by in Crossref: 89] [Cited by in F6Publishing: 75] [Article Influence: 8.9] [Reference Citation Analysis]
3 Jin S, Jin H, Hong S. Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics. Expert Opinion on Therapeutic Targets 2015;19:1319-37. [DOI: 10.1517/14728222.2015.1044975] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
4 Filss CP, Cicone F, Shah NJ, Galldiks N, Langen KJ. Amino acid PET and MR perfusion imaging in brain tumours. Clin Transl Imaging 2017;5:209-23. [PMID: 28680873 DOI: 10.1007/s40336-017-0225-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
5 Verger A, Langen K; Department of Nuclear Medicine & Nancyclotep Imaging Platform, CHRU Nancy, Lorraine University, France, IADI, INSERM, UMR 947, Lorraine University, Nancy, France, Department of Nuclear Medicine, University of Aachen, Aachen, Germany, Institute of Neuroscience and Medicine, Forschungszentrum Jülich, Jülich, Germany. PET Imaging in Glioblastoma: Use in Clinical Practice. In: De Vleeschouwer S, editor. Glioblastoma. Codon Publications; 2017. pp. 155-74. [DOI: 10.15586/codon.glioblastoma.2017.ch9] [Cited by in Crossref: 11] [Article Influence: 2.2] [Reference Citation Analysis]
6 Xiao J, Jin Y, Nie J, Chen F, Ma X. Diagnostic and grading accuracy of 18F-FDOPA PET and PET/CT in patients with gliomas: a systematic review and meta-analysis. BMC Cancer 2019;19:767. [PMID: 31382920 DOI: 10.1186/s12885-019-5938-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
7 Girard A, Le Reste PJ, Metais A, Chaboub N, Devillers A, Saint-Jalmes H, Jeune FL, Palard-Novello X. Additive Value of Dynamic FDOPA PET/CT for Glioma Grading. Front Med (Lausanne) 2021;8:705996. [PMID: 34307430 DOI: 10.3389/fmed.2021.705996] [Reference Citation Analysis]
8 Piroth MD, Galldiks N, Pinkawa M, Holy R, Stoffels G, Ermert J, Mottaghy FM, Shah NJ, Langen KJ, Eble MJ. Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume. Radiat Oncol 2016;11:87. [PMID: 27342976 DOI: 10.1186/s13014-016-0665-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
9 Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A, Budach V, Bütof R, Combs SE, Derlin T, Eiber M, Fendler WP, Furth C, Gani C, Gkika E, Grosu AL, Henkenberens C, Ilhan H, Löck S, Marnitz-Schulze S, Miederer M, Mix M, Nicolay NH, Niyazi M, Pöttgen C, Rödel CM, Schatka I, Schwarzenboeck SM, Todica AS, Weber W, Wegen S, Wiegel T, Zamboglou C, Zips D, Zöphel K, Zschaeck S, Thorwarth D, Troost EGC; “Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN”. Value of PET imaging for radiation therapy. Nuklearmedizin 2021. [PMID: 34261141 DOI: 10.1055/a-1525-7029] [Reference Citation Analysis]
10 Bell C, Dowson N, Puttick S, Gal Y, Thomas P, Fay M, Smith J, Rose S. Increasing feasibility and utility of (18)F-FDOPA PET for the management of glioma. Nucl Med Biol 2015;42:788-95. [PMID: 26162582 DOI: 10.1016/j.nucmedbio.2015.06.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
11 Ponisio MR, McConathy JE, Dahiya SM, Miller-Thomas MM, Rich KM, Salter A, Wang Q, LaMontagne PJ, Guzmán Pérez-Carrillo GJ, Benzinger TLS. Dynamic 18F-FDOPA-PET/MRI for the preoperative evaluation of gliomas: correlation with stereotactic histopathology. Neurooncol Pract 2020;7:656-67. [PMID: 33312679 DOI: 10.1093/nop/npaa044] [Reference Citation Analysis]
12 Renner DN, Jin F, Litterman AJ, Balgeman AJ, Hanson LM, Gamez JD, Chae M, Carlson BL, Sarkaria JN, Parney IF, Ohlfest JR, Pirko I, Pavelko KD, Johnson AJ. Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses. PLoS One 2015;10:e0125565. [PMID: 25933216 DOI: 10.1371/journal.pone.0125565] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
13 Galldiks N, Langen KJ, Pope WB. From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? Neuro Oncol 2015;17:1434-44. [PMID: 26130743 DOI: 10.1093/neuonc/nov118] [Cited by in Crossref: 111] [Cited by in F6Publishing: 83] [Article Influence: 15.9] [Reference Citation Analysis]
14 Lopez WO, Cordeiro JG, Albicker U, Doostkam S, Nikkhah G, Kirch RD, Trippel M, Reithmeier T. Correlation of (18)F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool. Onco Targets Ther 2015;8:3803-15. [PMID: 26719708 DOI: 10.2147/OTT.S87126] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
15 Donner D, Rozzanigo U, Amelio D, Sarubbo S, Scartoni D, Picori L, Amichetti M, Chioffi F, Chierichetti F. PET in brain tumors. Clin Transl Imaging 2019;7:45-60. [DOI: 10.1007/s40336-018-0307-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Verger A, Imbert L, Zaragori T. Dynamic amino-acid PET in neuro-oncology: a prognostic tool becomes essential. Eur J Nucl Med Mol Imaging 2021;48:4129-32. [PMID: 34518904 DOI: 10.1007/s00259-021-05530-w] [Reference Citation Analysis]
17 Kazda T, Dziacky A, Burkon P, Pospisil P, Slavik M, Rehak Z, Jancalek R, Slampa P, Slaby O, Lakomy R. Radiotherapy of Glioblastoma 15 Years after the Landmark Stupp's Trial: More Controversies than Standards? Radiol Oncol 2018;52:121-8. [PMID: 30018514 DOI: 10.2478/raon-2018-0023] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
18 Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A, Budach V, Bütof R, Combs SE, Derlin T, Eiber M, Fendler WP, Furth C, Gani C, Gkika E, Grosu AL, Henkenberens C, Ilhan H, Löck S, Marnitz-Schulze S, Miederer M, Mix M, Nicolay NH, Niyazi M, Pöttgen C, Rödel CM, Schatka I, Schwarzenboeck SM, Todica AS, Weber W, Wegen S, Wiegel T, Zamboglou C, Zips D, Zöphel K, Zschaeck S, Thorwarth D, Troost EGC; Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN. Value of PET imaging for radiation therapy. Strahlenther Onkol 2021;197:1-23. [PMID: 34259912 DOI: 10.1007/s00066-021-01812-2] [Reference Citation Analysis]
19 Grimm SA, Chamberlain MC. Anaplastic astrocytoma. CNS Oncol 2016;5:145-57. [PMID: 27230974 DOI: 10.2217/cns-2016-0002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
20 Rozenblum L, Bertaux M, Bielle F, Ollivier M, Choquet S, Garcilazo Y, Mokhtari K, Kas A. 18F-FDOPA PET/CT Findings in a Patient With Primary Cerebral Amyloidoma. Clin Nucl Med 2020;45:e206-7. [DOI: 10.1097/rlu.0000000000002959] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Kazda T, Pafundi DH, Kraling A, Bradley T, Lowe VJ, Brinkmann DH, Laack NN. Dosimetric impact of amino acid positron emission tomography imaging for target delineation in radiation treatment planning for high-grade gliomas. Phys Imaging Radiat Oncol 2018;6:94-100. [PMID: 33458396 DOI: 10.1016/j.phro.2018.06.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
22 Ruff M, Kizilbash S, Buckner J. Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development. Expert Rev Anticancer Ther 2020;20:355-63. [PMID: 32301635 DOI: 10.1080/14737140.2020.1757440] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Palumbo B, Buresta T, Nuvoli S, Spanu A, Schillaci O, Fravolini ML, Palumbo I. SPECT and PET serve as molecular imaging techniques and in vivo biomarkers for brain metastases. Int J Mol Sci 2014;15:9878-93. [PMID: 24897023 DOI: 10.3390/ijms15069878] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
24 Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol 2016;18:1199-208. [PMID: 27106405 DOI: 10.1093/neuonc/now058] [Cited by in Crossref: 336] [Cited by in F6Publishing: 275] [Article Influence: 56.0] [Reference Citation Analysis]
25 Kim M, Laramy JK, Gampa G, Parrish KE, Brundage R, Sarkaria JN, Elmquist WF. Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy. Drug Metab Dispos 2019;47:1403-14. [PMID: 31619389 DOI: 10.1124/dmd.119.088716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Cicone F, Filss CP, Minniti G, Rossi-Espagnet C, Papa A, Scaringi C, Galldiks N, Bozzao A, Shah NJ, Scopinaro F, Langen KJ. Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI. Eur J Nucl Med Mol Imaging 2015;42:905-15. [PMID: 25750084 DOI: 10.1007/s00259-015-3018-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
27 Verburg N, Koopman T, Yaqub M, Hoekstra OS, Lammertsma AA, Schwarte LA, Barkhof F, Pouwels PJW, Heimans JJ, Reijneveld JC, Rozemuller AJM, Vandertop WP, Wesseling P, Boellaard R, de Witt Hamer PC. Direct comparison of [11C] choline and [18F] FET PET to detect glioma infiltration: a diagnostic accuracy study in eight patients. EJNMMI Res 2019;9:57. [PMID: 31254208 DOI: 10.1186/s13550-019-0523-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Moreau A, Febvey O, Mognetti T, Frappaz D, Kryza D. Contribution of Different Positron Emission Tomography Tracers in Glioma Management: Focus on Glioblastoma. Front Oncol 2019;9:1134. [PMID: 31737567 DOI: 10.3389/fonc.2019.01134] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
29 Sipos D, László Z, Tóth Z, Kovács P, Tollár J, Gulybán A, Lakosi F, Repa I, Kovács A. Additional Value of 18F-FDOPA Amino Acid Analog Radiotracer to Irradiation Planning Process of Patients With Glioblastoma Multiforme. Front Oncol 2021;11:699360. [PMID: 34295825 DOI: 10.3389/fonc.2021.699360] [Reference Citation Analysis]
30 Youland RS, Kreofsky CR, Schomas DA, Brown PD, Buckner JC, Laack NN. The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma. J Neurooncol 2017;135:535-43. [PMID: 28836106 DOI: 10.1007/s11060-017-2599-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
31 Chung C, Metser U, Ménard C. Advances in Magnetic Resonance Imaging and Positron Emission Tomography Imaging for Grading and Molecular Characterization of Glioma. Semin Radiat Oncol 2015;25:164-71. [PMID: 26050586 DOI: 10.1016/j.semradonc.2015.02.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
32 Dupont C, Betrouni N, Reyns N, Vermandel M. On Image Segmentation Methods Applied to Glioblastoma: State of Art and New Trends. IRBM 2016;37:131-43. [DOI: 10.1016/j.irbm.2015.12.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 3] [Article Influence: 4.2] [Reference Citation Analysis]
33 Hassanzadeh C, Rudra S, Ma S, Brenneman R, Huang Y, Henke L, Abraham C, Campian J, Tsien C, Huang J. Evaluation of interim MRI changes during limited-field radiation therapy for glioblastoma and implications for treatment planning. Radiother Oncol 2021;158:237-43. [PMID: 33587967 DOI: 10.1016/j.radonc.2021.01.040] [Reference Citation Analysis]
34 Herholz K. Brain Tumors: An Update on Clinical PET Research in Gliomas. Semin Nucl Med 2017;47:5-17. [PMID: 27987557 DOI: 10.1053/j.semnuclmed.2016.09.004] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
35 Kosztyla R, Chan EK, Hsu F, Wilson D, Ma R, Cheung A, Zhang S, Moiseenko V, Benard F, Nichol A. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers. Int J Radiat Oncol Biol Phys 2013;87:1100-6. [PMID: 24161427 DOI: 10.1016/j.ijrobp.2013.09.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
36 Verger A, Arbizu J, Law I. Role of amino-acid PET in high-grade gliomas: limitations and perspectives. Q J Nucl Med Mol Imaging 2018;62:254-66. [PMID: 29696948 DOI: 10.23736/S1824-4785.18.03092-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
37 Da Ros M, De Gregorio V, Iorio AL, Giunti L, Guidi M, de Martino M, Genitori L, Sardi I. Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier. Int J Mol Sci 2018;19:E2879. [PMID: 30248992 DOI: 10.3390/ijms19102879] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
38 Kasten BB, Udayakumar N, Leavenworth JW, Wu AM, Lapi SE, McConathy JE, Sorace AG, Bag AK, Markert JM, Warram JM. Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. Theranostics 2019;9:5085-104. [PMID: 31410203 DOI: 10.7150/thno.34415] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
39 Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, Elmquist WF. Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. Pharm Res 2018;35:177. [PMID: 30003344 DOI: 10.1007/s11095-018-2455-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
40 Dhermain F. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches. Chin J Cancer 2014;33:16-24. [PMID: 24384237 DOI: 10.5732/cjc.013.10217] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
41 Morana G, Tortora D, Bottoni G, Puntoni M, Piatelli G, Garibotto F, Barra S, Giannelli F, Cistaro A, Severino M, Verrico A, Milanaccio C, Massimino M, Garrè ML, Rossi A, Piccardo A. Correlation of multimodal 18F-DOPA PET and conventional MRI with treatment response and survival in children with diffuse intrinsic pontine gliomas. Theranostics 2020;10:11881-91. [PMID: 33204317 DOI: 10.7150/thno.50598] [Reference Citation Analysis]
42 Albert NL, Winkelmann I, Suchorska B, Wenter V, Schmid-tannwald C, Mille E, Todica A, Brendel M, Tonn J, Bartenstein P, la Fougère C. Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans. Eur J Nucl Med Mol Imaging 2016;43:1105-14. [DOI: 10.1007/s00259-015-3276-2] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 9.4] [Reference Citation Analysis]
43 Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol 2018;20:184-91. [PMID: 29016900 DOI: 10.1093/neuonc/nox175] [Cited by in Crossref: 170] [Cited by in F6Publishing: 165] [Article Influence: 56.7] [Reference Citation Analysis]
44 Meyer HS, Liesche-Starnecker F, Mustafa M, Yakushev I, Wiestler B, Meyer B, Gempt J. [18F]FET PET Uptake Indicates High Tumor and Low Necrosis Content in Brain Metastasis. Cancers (Basel) 2021;13:355. [PMID: 33478030 DOI: 10.3390/cancers13020355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Jung JH, Ahn BC. Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors. Brain Tumor Res Treat 2018;6:47-53. [PMID: 30381916 DOI: 10.14791/btrt.2018.6.e13] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
46 Zhu Y, Lin Y, Hosmane NS. Synthesis and in vitro anti-tumor activity of carboranyl levodopa. Bioorg Chem 2019;90:103090. [PMID: 31260876 DOI: 10.1016/j.bioorg.2019.103090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Pellerin A, Khalifé M, Sanson M, Rozenblum-Beddok L, Bertaux M, Soret M, Galanaud D, Dormont D, Kas A, Pyatigorskaya N. Simultaneously acquired PET and ASL imaging biomarkers may be helpful in differentiating progression from pseudo-progression in treated gliomas. Eur Radiol 2021. [PMID: 33787971 DOI: 10.1007/s00330-021-07732-0] [Reference Citation Analysis]
48 John F, Bosnyák E, Robinette NL, Amit-Yousif AJ, Barger GR, Shah KD, Michelhaugh SK, Klinger NV, Mittal S, Juhász C. Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival. Neuro Oncol 2019;21:264-73. [PMID: 30346623 DOI: 10.1093/neuonc/noy169] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
49 Oberoi RK, Parrish KE, Sio TT, Mittapalli RK, Elmquist WF, Sarkaria JN. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro Oncol 2016;18:27-36. [PMID: 26359209 DOI: 10.1093/neuonc/nov164] [Cited by in Crossref: 121] [Cited by in F6Publishing: 117] [Article Influence: 17.3] [Reference Citation Analysis]
50 Galldiks N, Niyazi M, Grosu AL, Kocher M, Langen KJ, Law I, Minniti G, Kim MM, Tsien C, Dhermain F, Soffietti R, Mehta MP, Weller M, Tonn JC. Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. Neuro Oncol 2021;23:881-93. [PMID: 33538838 DOI: 10.1093/neuonc/noab013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
51 Todeschi J, Bund C, Cebula H, Chibbaro S, Lhermitte B, Pin Y, Lefebvre F, Namer IJ, Proust F. Diagnostic value of fusion of metabolic and structural images for stereotactic biopsy of brain tumors without enhancement after contrast medium injection. Neurochirurgie 2019;65:357-64. [PMID: 31560911 DOI: 10.1016/j.neuchi.2019.08.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
52 Press RH, Zhong J, Gurbani SS, Weinberg BD, Eaton BR, Shim H, Shu HG. The Role of Standard and Advanced Imaging for the Management of Brain Malignancies From a Radiation Oncology Standpoint. Neurosurgery 2019;85:165-79. [DOI: 10.1093/neuros/nyy461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
53 Helali M, Moreau M, Le Fèvre C, Heimburger C, Bund C, Goichot B, Veillon F, Hubelé F, Charpiot A, Noel G, Imperiale A. 18F-FDOPA PET/CT Combined with MRI for Gross Tumor Volume Delineation in Patients with Skull Base Paraganglioma. Cancers (Basel) 2019;11:E54. [PMID: 30626096 DOI: 10.3390/cancers11010054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
54 Heiss W. Clinical Impact of Amino Acid PET in Gliomas. J Nucl Med 2014;55:1219-20. [DOI: 10.2967/jnumed.114.142661] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
55 Girard A, Le Reste PJ, Metais A, Carsin Nicol B, Chiforeanu DC, Bannier E, Campillo-Gimenez B, Devillers A, Palard-Novello X, Le Jeune F. Combining 18F-DOPA PET and MRI with perfusion-weighted imaging improves delineation of high-grade subregions in enhancing and non-enhancing gliomas prior treatment: a biopsy-controlled study. J Neurooncol 2021. [PMID: 34686993 DOI: 10.1007/s11060-021-03873-w] [Reference Citation Analysis]
56 Levin VA, Tonge PJ, Gallo JM, Birtwistle MR, Dar AC, Iavarone A, Paddison PJ, Heffron TP, Elmquist WF, Lachowicz JE, Johnson TW, White FM, Sul J, Smith QR, Shen W, Sarkaria JN, Samala R, Wen PY, Berry DA, Petter RC. CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro Oncol 2015;17 Suppl 6:vi1-26. [PMID: 26403167 DOI: 10.1093/neuonc/nov169] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
57 Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, la Fougère C, Langen KJ, Lopci E, Lowe V, McConathy J, Quick HH, Sattler B, Schuster DM, Tonn JC, Weller M. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging 2019;46:540-57. [PMID: 30519867 DOI: 10.1007/s00259-018-4207-9] [Cited by in Crossref: 138] [Cited by in F6Publishing: 117] [Article Influence: 34.5] [Reference Citation Analysis]
58 Villena Martín M, Pena Pardo FJ, Jiménez Aragón F, Borras Moreno JM, García Vicente AM. Metabolic targeting can improve the efficiency of brain tumor biopsies. Seminars in Oncology 2020;47:148-54. [DOI: 10.1053/j.seminoncol.2020.04.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NY, Curtin NJ, Elmquist WF, Sarkaria JN. Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Mol Cancer Ther 2015;14:2735-43. [PMID: 26438157 DOI: 10.1158/1535-7163.MCT-15-0553] [Cited by in Crossref: 50] [Cited by in F6Publishing: 31] [Article Influence: 7.1] [Reference Citation Analysis]
60 Youland RS, Pafundi DH, Brinkmann DH, Lowe VJ, Morris JM, Kemp BJ, Hunt CH, Giannini C, Parney IF, Laack NN. Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. J Neurooncol 2018;137:583-91. [PMID: 29330751 DOI: 10.1007/s11060-018-2750-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
61 Hu LS, Ning S, Eschbacher JM, Gaw N, Dueck AC, Smith KA, Nakaji P, Plasencia J, Ranjbar S, Price SJ, Tran N, Loftus J, Jenkins R, O'Neill BP, Elmquist W, Baxter LC, Gao F, Frakes D, Karis JP, Zwart C, Swanson KR, Sarkaria J, Wu T, Mitchell JR, Li J. Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma. PLoS One 2015;10:e0141506. [PMID: 26599106 DOI: 10.1371/journal.pone.0141506] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 9.6] [Reference Citation Analysis]
62 Ganipineni LP, Danhier F, Préat V. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment. J Control Release 2018;281:42-57. [PMID: 29753958 DOI: 10.1016/j.jconrel.2018.05.008] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 16.5] [Reference Citation Analysis]
63 Kim MM, Parolia A, Dunphy MP, Venneti S. Non-invasive metabolic imaging of brain tumours in the era of precision medicine. Nat Rev Clin Oncol 2016;13:725-39. [PMID: 27430748 DOI: 10.1038/nrclinonc.2016.108] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 9.7] [Reference Citation Analysis]
64 Juhász C, Dwivedi S, Kamson DO, Michelhaugh SK, Mittal S. Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors. Mol Imaging 2014;13. [PMID: 24825818 DOI: 10.2310/7290.2014.00015] [Cited by in Crossref: 79] [Cited by in F6Publishing: 55] [Article Influence: 11.3] [Reference Citation Analysis]
65 Keil VC, Pintea B, Gielen GH, Greschus S, Fimmers R, Gieseke J, Simon M, Schild HH, Hadizadeh DR. Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma: a prospective double-blinded evaluation of selection benefits. J Neurooncol 2017;133:155-63. [PMID: 28425048 DOI: 10.1007/s11060-017-2424-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
66 Gupta SK, Smith EJ, Mladek AC, Tian S, Decker PA, Kizilbash SH, Kitange GJ, Sarkaria JN. PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity. Front Oncol 2018;8:670. [PMID: 30723695 DOI: 10.3389/fonc.2018.00670] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
67 Riemenschneider MJ, Louis DN, Weller M, Hau P. Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach. Acta Neuropathol 2013;126:21-37. [PMID: 23689616 DOI: 10.1007/s00401-013-1127-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
68 Keunen O, Taxt T, Grüner R, Lund-Johansen M, Tonn JC, Pavlin T, Bjerkvig R, Niclou SP, Thorsen F. Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies. Adv Drug Deliv Rev 2014;76:98-115. [PMID: 25078721 DOI: 10.1016/j.addr.2014.07.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
69 Kasten BB, Jiang K, Cole D, Jani A, Udayakumar N, Gillespie GY, Lu G, Dai T, Rosenthal EL, Markert JM, Rao J, Warram JM. Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models. Eur J Nucl Med Mol Imaging 2020;47:1412-26. [PMID: 31773232 DOI: 10.1007/s00259-019-04607-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
70 Qian J, Herman MG, Brinkmann DH, Laack NN, Kemp BJ, Hunt CH, Lowe V, Pafundi DH. Prediction of MGMT Status for Glioblastoma Patients Using Radiomics Feature Extraction From 18F-DOPA-PET Imaging. Int J Radiat Oncol Biol Phys 2020;108:1339-46. [PMID: 32634544 DOI: 10.1016/j.ijrobp.2020.06.073] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
71 Pokorny JL, Calligaris D, Gupta SK, Iyekegbe DO, Mueller D, Bakken KK, Carlson BL, Schroeder MA, Evans DL, Lou Z. The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Clin Cancer Res. 2015;21:1916-1924. [PMID: 25609063 DOI: 10.1158/1078-0432.CCR-14-2588] [Cited by in Crossref: 59] [Cited by in F6Publishing: 41] [Article Influence: 8.4] [Reference Citation Analysis]
72 Najjar AM, Johnson JM, Schellingerhout D. The Emerging Role of Amino Acid PET in Neuro-Oncology. Bioengineering (Basel) 2018;5:E104. [PMID: 30487391 DOI: 10.3390/bioengineering5040104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
73 Unterrainer M, Eze C, Ilhan H, Marschner S, Roengvoraphoj O, Schmidt-Hegemann NS, Walter F, Kunz WG, Rosenschöld PMA, Jeraj R, Albert NL, Grosu AL, Niyazi M, Bartenstein P, Belka C. Recent advances of PET imaging in clinical radiation oncology. Radiat Oncol 2020;15:88. [PMID: 32317029 DOI: 10.1186/s13014-020-01519-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
74 Sun A, Liu X, Tang G. Carbon-11 and Fluorine-18 Labeled Amino Acid Tracers for Positron Emission Tomography Imaging of Tumors. Front Chem 2017;5:124. [PMID: 29379780 DOI: 10.3389/fchem.2017.00124] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
75 Miller-Thomas MM, Benzinger TL. Neurologic Applications of PET/MR Imaging. Magn Reson Imaging Clin N Am 2017;25:297-313. [PMID: 28390530 DOI: 10.1016/j.mric.2016.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
76 Pruis IJ, van Dongen GAMS, Veldhuijzen van Zanten SEM. The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors. Int J Mol Sci 2020;21:E1029. [PMID: 32033160 DOI: 10.3390/ijms21031029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
77 Shampo MA, Kyle RA. Emily Perkins Bissell. JAMA. 1981;245:163. [PMID: 7005466 DOI: 10.1016/j.heliyon.2020.e03340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
78 Fei B, Schuster DM. PET Molecular Imaging-Directed Biopsy: A Review. AJR Am J Roentgenol 2017;209:255-69. [PMID: 28504563 DOI: 10.2214/AJR.17.18047] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 4.6] [Reference Citation Analysis]
79 Cicone F, Carideo L, Scaringi C, Arcella A, Giangaspero F, Scopinaro F, Minniti G. 18F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma. Ann Nucl Med 2019;33:295-302. [PMID: 30607877 DOI: 10.1007/s12149-018-01328-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
80 Kosztyla R, Raman S, Moiseenko V, Reinsberg SA, Toyota B, Nichol A. Dose-painted volumetric modulated arc therapy of high-grade glioma using 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine positron emission tomography. Br J Radiol 2019;92:20180901. [PMID: 31017449 DOI: 10.1259/bjr.20180901] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
81 Hu LS, Hawkins-Daarud A, Wang L, Li J, Swanson KR. Imaging of intratumoral heterogeneity in high-grade glioma. Cancer Lett 2020;477:97-106. [PMID: 32112907 DOI: 10.1016/j.canlet.2020.02.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
82 Hu LS, Yoon H, Eschbacher JM, Baxter LC, Dueck AC, Nespodzany A, Smith KA, Nakaji P, Xu Y, Wang L, Karis JP, Hawkins-Daarud AJ, Singleton KW, Jackson PR, Anderies BJ, Bendok BR, Zimmerman RS, Quarles C, Porter-Umphrey AB, Mrugala MM, Sharma A, Hoxworth JM, Sattur MG, Sanai N, Koulemberis PE, Krishna C, Mitchell JR, Wu T, Tran NL, Swanson KR, Li J. Accurate Patient-Specific Machine Learning Models of Glioblastoma Invasion Using Transfer Learning. AJNR Am J Neuroradiol 2019;40:418-25. [PMID: 30819771 DOI: 10.3174/ajnr.A5981] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
83 Kinoshita M, Uchikoshi M, Tateishi S, Miyazaki S, Sakai M, Ozaki T, Asai K, Fujita Y, Matsuhashi T, Kanemura Y, Shimosegawa E, Hatazawa J, Nakatsuka SI, Kishima H, Nakanishi K. Magnetic Resonance Relaxometry for Tumor Cell Density Imaging for Glioma: An Exploratory Study via 11C-Methionine PET and Its Validation via Stereotactic Tissue Sampling. Cancers (Basel) 2021;13:4067. [PMID: 34439221 DOI: 10.3390/cancers13164067] [Reference Citation Analysis]
84 Song S, Cheng Y, Ma J, Wang L, Dong C, Wei Y, Xu G, An Y, Qi Z, Lin Q, Lu J. Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study. Eur J Nucl Med Mol Imaging 2020;47:1458-67. [PMID: 31919633 DOI: 10.1007/s00259-019-04656-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
85 Suchorska B, Tonn JC, Jansen NL. PET imaging for brain tumor diagnostics. Curr Opin Neurol 2014;27:683-8. [PMID: 25333605 DOI: 10.1097/WCO.0000000000000143] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
86 Becker CM, Oberoi RK, McFarren SJ, Muldoon DM, Pafundi DH, Pokorny JL, Brinkmann DH, Ohlfest JR, Sarkaria JN, Largaespada DA, Elmquist WF. Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma. Neuro Oncol 2015;17:1210-9. [PMID: 25972455 DOI: 10.1093/neuonc/nov081] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
87 Li D, Patel CB, Xu G, Iagaru A, Zhu Z, Zhang L, Cheng Z. Visualization of Diagnostic and Therapeutic Targets in Glioma With Molecular Imaging. Front Immunol 2020;11:592389. [PMID: 33193439 DOI: 10.3389/fimmu.2020.592389] [Reference Citation Analysis]
88 Bell C, Rose S, Puttick S, Pagnozzi A, Poole CM, Gal Y, Thomas P, Fay M, Jeffree RL, Dowson N. Dual acquisition of (18)F-FMISO and (18)F-FDOPA. Phys Med Biol 2014;59:3925-49. [PMID: 24958083 DOI: 10.1088/0031-9155/59/14/3925] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
89 Somme F, Bender L, Namer IJ, Noël G, Bund C. Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature. Cancer Imaging 2020;20:70. [PMID: 33023662 DOI: 10.1186/s40644-020-00348-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
90 Fraioli F, Shankar A, Hyare H, Ferrazzoli V, Militano V, Samandouras G, Mankad K, Solda F, Zaccagna F, Mehdi E, Lyasheva M, Bomanji J, Novruzov F. The use of multiparametric 18F-fluoro-L-3,4-dihydroxy-phenylalanine PET/MRI in post-therapy assessment of patients with gliomas. Nucl Med Commun 2020;41:517-25. [PMID: 32282634 DOI: 10.1097/MNM.0000000000001184] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
91 Kim M, Ma DJ, Calligaris D, Zhang S, Feathers RW, Vaubel RA, Meaux I, Mladek AC, Parrish KE, Jin F, Barriere C, Debussche L, Watters J, Tian S, Decker PA, Eckel-Passow JE, Kitange GJ, Johnson AJ, Parney IF, Anastasiadis PZ, Agar NYR, Elmquist WF, Sarkaria JN. Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Mol Cancer Ther 2018;17:1893-901. [PMID: 29970480 DOI: 10.1158/1535-7163.MCT-17-0600] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
92 Belanova R, Sprlakova-Pukova A, Standara M, Janu E, Koukalova R, Kristek J, Burkon P, Kolouskova I, Prochazka T, Pospisil P, Chakravarti A, Slampa P, Slaby O, Kazda T. In silico study of pseudoprogression in glioblastoma: collaboration of radiologists and radiation oncologists in the estimation of extent of high dose RT region. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2020;164:307-13. [PMID: 31544900 DOI: 10.5507/bp.2019.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
93 Girard A, Saint-Jalmes H, Chaboub N, Le Reste PJ, Metais A, Devillers A, Le Jeune F, Palard-Novello X. Optimization of time frame binning for FDOPA uptake quantification in glioma. PLoS One 2020;15:e0232141. [PMID: 32320440 DOI: 10.1371/journal.pone.0232141] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
94 Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Shen Y, Feng Y, Protter AA, Elmquist WF, Sarkaria JN. Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Mol Cancer Ther 2017;16:2735-46. [PMID: 28947502 DOI: 10.1158/1535-7163.MCT-17-0365] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 5.4] [Reference Citation Analysis]
95 Galldiks N, Langen KJ, Albert NL, Chamberlain M, Soffietti R, Kim MM, Law I, Le Rhun E, Chang S, Schwarting J, Combs SE, Preusser M, Forsyth P, Pope W, Weller M, Tonn JC. PET imaging in patients with brain metastasis-report of the RANO/PET group. Neuro Oncol 2019;21:585-95. [PMID: 30615138 DOI: 10.1093/neuonc/noz003] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 29.5] [Reference Citation Analysis]
96 Rossi Espagnet MC, Romano A, Mancuso V, Cicone F, Napolitano A, Scaringi C, Minniti G, Bozzao A. Multiparametric evaluation of low grade gliomas at follow-up: comparison between diffusion and perfusion MR with (18)F-FDOPA PET. Br J Radiol 2016;89:20160476. [PMID: 27505026 DOI: 10.1259/bjr.20160476] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
97 Hu LS, Brat DJ, Bloch O, Ramkissoon S, Lesser GJ. The Practical Application of Emerging Technologies Influencing the Diagnosis and Care of Patients With Primary Brain Tumors. Am Soc Clin Oncol Educ Book 2020;40:1-12. [PMID: 32324425 DOI: 10.1200/EDBK_280955] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
98 Heiss WD. [PET in gliomas. Overview of current studies]. Nuklearmedizin 2014;53:163-71; quiz N32. [PMID: 24853278 DOI: 10.3413/Nukmed-0662-14-04] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
99 Karlberg A, Berntsen EM, Johansen H, Skjulsvik AJ, Reinertsen I, Dai HY, Xiao Y, Rivaz H, Borghammer P, Solheim O, Eikenes L. 18F-FACBC PET/MRI in Diagnostic Assessment and Neurosurgery of Gliomas. Clin Nucl Med 2019;44:550-9. [PMID: 31107743 DOI: 10.1097/RLU.0000000000002610] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
100 Dowson N, Thomas P, Fay M, Jeffree RL, Gal Y, Bourgeat P, Smith J, Winter C, Coulthard A, Salvado O, Crozier S, Rose S. Early prediction of treatment response in advanced gliomas with (18)F-dopa positron-emission tomography. Curr Oncol 2014;21:e172-8. [PMID: 24523617 DOI: 10.3747/co.21.1772] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
101 Cicone F, Carideo L, Minniti G, Scopinaro F. The mean striatal 18F-DOPA uptake is not a reliable cut-off threshold for biological tumour volume definition of glioma. Eur J Nucl Med Mol Imaging 2019;46:1051-3. [DOI: 10.1007/s00259-019-4276-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
102 Patel CB, Fazzari E, Chakhoyan A, Yao J, Raymond C, Nguyen H, Manoukian J, Nguyen N, Pope W, Cloughesy TF, Nghiemphu PL, Czernin J, Lai A, Ellingson BM. 18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. J Neurooncol 2018;139:399-409. [PMID: 29679199 DOI: 10.1007/s11060-018-2877-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]